sgp130 in Chronic Human Liver Disease

Status Completed

Clinical Trial Summary

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Clinical Trial Description

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00770198
Study type	Observational
Source	Erasme University Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 2005
Completion date	October 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00708617` - FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease	N/A
Completed	`NCT00990639` - Effect of Candesartan in Alcoholic Liver Fibrosis	Phase 1/Phase 2
Recruiting	`NCT04106518` - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Recruiting	`NCT04666402` - Integrated Diagnostics for Early Diagnosis of Liver Disease
Recruiting	`NCT02331745` - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure	Phase 4
Completed	`NCT01501162` - Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease	Phase 4
Recruiting	`NCT05895890` - French National MICMAF Cohort
Completed	`NCT04557774` - Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Recruiting	`NCT03267069` - Evaluating Alcohol Use in Alcoholic Liver Disease
Recruiting	`NCT03295812` - Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)	N/A
Recruiting	`NCT05855031` - The Liver Care Trial	N/A
Not yet recruiting	`NCT03503708` - Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease	N/A
Completed	`NCT02796469` - Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis	N/A
Completed	`NCT02140294` - Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease	N/A
Recruiting	`NCT03209791` - Ethanol Induces Skeletal Muscle Autophagy
Recruiting	`NCT04736966` - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease	Phase 1
Recruiting	`NCT04400604` - Study of Alcohol-related Liver Disease in Europe
Completed	`NCT03402256` - Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients	N/A
Completed	`NCT01711125` - Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease	Phase 3
Active, not recruiting	`NCT03863730` - Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota	N/A